Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GRITSTONE BIO, INC.

(GRTS)
  Report
Real-time Estimate Cboe BZX  -  02:10 2022-10-05 pm EDT
2.555 USD   -3.95%
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase 1/2 Study; Shares Rise
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gritstone Oncology : Baird Downgrades Gritstone Oncology to Underperform From Outperform; Price Target is $8

01/20/2021 | 08:02am EDT


© MT Newswires 2021
All news about GRITSTONE BIO, INC.
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase ..
MT
09/12Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Trea..
AQ
09/12Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Pat..
CI
09/01Gritstone to Participate in Two Upcoming Investor Conferences
AQ
08/22Goldman Sachs Downgrades Gritstone bio to Sell From Neutral; Price Target is $2
MT
08/17Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANI..
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study..
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 19,2 M - -
Net income 2022 -123 M - -
Net cash 2022 23,0 M - -
P/E ratio 2022 -1,72x
Yield 2022 -
Capitalization 194 M 194 M -
EV / Sales 2022 8,91x
EV / Sales 2023 14,1x
Nbr of Employees 193
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,66 $
Average target price 11,33 $
Spread / Average Target 326%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Executive VP & Head-Research & Development
Erin E. Jones Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-79.32%194
CSL LIMITED-1.14%90 052
SAMSUNG BIOLOGICS CO.,LTD.-10.19%40 706
BIOGEN INC.11.47%38 810
WUXI BIOLOGICS (CAYMAN) INC.-47.81%26 225
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 439